Logo

Bayer and Evotec Join Forces to Develop Treatment for Cardiovascular Diseases

Share this
Bayer

Bayer and Evotec Join Forces to Develop Treatment for Cardiovascular Diseases

Shots:

  • Bayer and Evotec have shifted the aim of their strategic agreement to develop precision therapeutics for addressing cardiovascular diseases (CVDs)
  • The partnership will employ Evotec's disease modeling abilities leveraging human induced pluripotent stem cells (iPSCs) to identify and validate targets for cardiovascular diseases
  • Under the collaboration, both Bayer & Evotec will provide drug targets & advanced technology platforms to develop candidates. They will jointly handle pre-clinical development, with Bayer taking responsibility for clinical development & commercialization. Financial terms were undisclosed

Ref: Bayer | Image: Bayer

Related News:- Dewpoint Therapeutics Collaborates with Evotec to Accelerate its Oncology Pipeline

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions